Insmed jumps after US FDA lifts hold on lung disease programme
This article was originally published in Scrip
Executive Summary
Investors sent shares of Insmed soaring as high as 45% on 20 January after the Monmouth, New Jersey biotech said the US FDA lifted the clinical hold placed on Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease.